Long-term Observational Study to Evaluate the DFS and OS of Adjuvant FOLFIRINOX Regimen in Pancreatic Cancer Patients

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age19+

SponsorHK inno.N Corporation

About this trial

This study is designed to evaluate the safety and efficacy of adjuvant FOLFIRINOX regimen in pancreatic cancer patients after curative surgery.

Age over 19 at the time of obtaining the informed consent form

Planning to FOLFIRINOX as adjuvant therapy after pancreatic cancer surgery

ECOG 0 or 1

Scheduled to RO or R1 resection

FOLFIRINOX contraindications among the drug approval requirements

Palliative Therapy

Experienced toxic reactions or Hypersensitivity reactions of FOLFIRINOX

No trial groups listed

HK inno.N Corporation

Lead sponsor